Merck & Co Inc

MRK remains structurally bullish, trading above its rising 50- and 200-day SMAs, but short-term momentum has weakened as price sits below the 9- and 20-day EMAs and RSI approaches oversold. Execution is deferred; we will stalk for a pullback into the key support zone around the 50-day SMA before engaging the long side.

• ↑Robust pipeline: 20+ product launches with $70B revenue potential.
• ↑INTerpath-001 melanoma vaccine trial showed survival improvements.
• ↓Keytruda exclusivity ends, risking $8.4B annual sales decline.